Publications

August 1, 2023

Awareness of prescribing practices helps identify opportunities to improve antibiotic use (AU).

Publications

August 10, 2023

Roberto C Molina-Quiroz, Cecilia A Silva-Valenzuela,

Bacteriophages (phages) are viruses that specifically infect bacteria. These viruses were discovered a century ago and have been used as a model system in microbial genetics and molecular biology. In order to survive, bacteria have to quickly adapt to phage challenges in their natural settings. In turn, phages continuously develop/evolve mechanisms for battling host defenses. A deeper understanding of the arms race between bacteria and phages is essential for the rational design of phage-based prophylaxis and therapies to prevent and treat bacterial infections. Vibrio species and their phages (vibriophages) are a suitable model to study these interactions. Phages are highly ubiquitous in aquatic environments and Vibrio are waterborne bacteria that must survive the constant attack by phages for successful transmission to their hosts. Here, we review relevant literature from the past two years to delve into the molecular interactions of Vibrio species and their phages in aquatic niches.

Publications

August 22, 2023

Tori Kinamon, Ramya Gopinath, Ursula Waack, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg, Scott Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers, Vance G Fowler, Jr, Sumati Nambiar, Peter Kim, Helen W Boucher

Publications

September 8, 2023

Heather K. Amato, Fernanda Loayza, Liseth Salinas, Diana Paredes, Daniela García, Soledad Sarzosa, Carlos Saraiva-Garcia, Timothy J. Johnson, Amy J. Pickering, Lee W. Riley, Gabriel Trueba & Jay P. Graham

Publications

September 13, 2023

HIV drug resistance (HIVDR) is a major challenge to the effectiveness of antiretroviral therapy. Global efforts in addressing HIVDR require clear, transparent, and replicable reporting in HIVDR studies. We describe the rationale and recommended use of a checklist that should be included in reports of HIVDR incidence and prevalence. After preliminary consultations with experts on HIVDR and establishing the need for guidance on HIVDR reporting, we used a sequential, explanatory, mixed methods approach to create the checklist; together with the accompanying articles, the checklist was reviewed by the authors and validated externally. The checklist for studies on HIVDR prevalence or incidence (CEDRIC-HIV) includes 15 recommended items that would enhance transparency and facilitate interpretation, comparability, and replicability of HIVDR studies. CEDRIC-HIV will help authors of HIVDR studies prepare research reports and assist reviewers and editors in assessments of completeness of reporting. The checklist will also facilitate statistical pooling and interpretation of HIVDR data.

Publications

September 20, 2023

D. R. Snydman, L. A. McDermott, C. M. Thorpe, E. J. C. Goldstein, A. N. Schuetz, S. Johnson, D. N. Gerding, L. Gluck, D. Bourdas, K. C. Carroll, C. K. Lancaster, K. W. Garey, Q. Wang, S. T. Walk, E. Duperchy

Publications

September 22, 2023

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are frequently caused by multidrug-resistant organisms. Patient-centered endpoints in clinical trials are needed to develop new antibiotics for HABP/VABP. Desirability of outcome ranking (DOOR) is a paradigm for the design, analysis, and interpretation of clinical trials based on a patient-centered, benefit-risk evaluation.

Publications

October 4, 2023

Heather L. Shearer, Paul E. Pace, Leah M. Smith, Peter C. Fineran, Allison J. Matthews, Andrew Camilli, Nina Dickerhof, Mark B. Hampton

Publications

October 16, 2023

Scott R Evans, Robin Patel, Toshimitsu Hamasaki, Jessica Howard-Anderson, Tori Kinamon, Heather A King, Deborah Collyar, Heather R Cross, Henry F Chambers, Vance G Fowler, Jr, Helen W Boucher

Publications

October 16, 2023

The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.